Last updated: February 16, 2026
What is the current market landscape for NDC 25021-0502 (Sovaldi)?
NDC 25021-0502 corresponds to the drug Sovaldi (sofosbuvir), developed by Gilead Sciences. This medication is a nucleoside analog polymerase inhibitor indicated for chronic hepatitis C virus (HCV) infection. First approved by the FDA in December 2013, Sovaldi revolutionized HCV treatment through its high efficacy and short treatment durations.
The drug's market presence hinges on HCV prevalence, treatment guidelines, and competition. As of 2023, there are approximately 2.5 million Americans estimated to be infected with HCV, with 10-15% progressing to advanced liver disease.
How does Sovaldi compare to alternatives in the hepatitis C treatment market?
Sovaldi was among the earliest direct-acting antivirals (DAAs) that offered sustained virologic response (SVR) rates exceeding 90%. However, subsequent developments have expanded options:
- Harvoni (ledipasvir/sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
These competitors often have comparable or higher efficacy, broader genotypic coverage, shorter durations, or fewer side effects. Price competition has intensified significantly since initial launch, influencing the market share of Sovaldi.
What is the cost structure for NDC 25021-0502?
Sovaldi's list price in 2014 was approximately $84,000 for a 12-week course. Gilead initially held a dominant market position, but pricing has decreased due to generic competition and negotiations:
- In 2015, some health programs and insurers negotiated discounts reducing costs by up to 50%.
- The U.S. Department of Veterans Affairs (VA) secured prices around $1,000 per pill, totaling approximately $24,000 for a typical course, significantly lower than initial retail.
- Puerto Rican Medicaid programs negotiated prices around $54,000 per treatment, compared to the original $84,000.
Pricing variations depend on payer contracts, geographic location, and patient-specific factors. The trend toward lower prices continues as generics enter markets in India and other countries.
What are the key factors affecting market share and future sales volume?
- Epidemiology: Continued identification and treatment of HCV carriers expand the total addressable population.
- Treatment guidelines: Updated recommendations favor shorter, pangenotypic regimens that may mitigate Sovaldi’s market dominance.
- Pricing pressure: Patent expirations and generic entries in 2025-2027 could see a decline in Sovaldi's market share.
- Competition: The emergence of more convenient or cost-effective regimens reduces demand for Sovaldi.
- Regulatory decisions: Indications, approvals, and potential patent litigations influence product lifecycle.
What is the projection for the price trend of NDC 25021-0502 over the next five years?
Given the patent status and evolving competitive landscape:
| Year |
Price Range (per course) |
Key Factors |
| 2023 |
$20,000 – $54,000 |
Discounted contracts, generic market entry in some countries |
| 2024 |
$15,000 – $50,000 |
Increased generic penetration, hospital-based negotiations |
| 2025 |
$10,000 – $40,000 |
Patent expiration in major markets, generic availability |
| 2026 |
$5,000 – $30,000 |
Expanded generics, biosimilars, increasingly lower prices |
| 2027 |
$2,000 – $20,000 |
Market consolidation, patent completions, generics dominance |
These estimates reflect decreasing prices driven by patent expirations, international generic proliferation, and declining market exclusivity.
What are the implications for stakeholders?
- Gilead: Focus on patent extensions, formulation innovations, or newer combination therapies.
- Payers: Seek discounts, preferential formulary placement, and negotiations to manage escalating healthcare costs.
- Manufacturers of generics: Accelerate entry in markets with patent expiry, leveraging cost advantages.
- Patients: Access to more affordable therapies in emerging markets but potential variation in quality and availability.
Key Takeaways
- NDC 25021-0502 (Sovaldi) remains relevant mainly in markets with delayed patent expiry and in certain therapeutic niches.
- Pricing has significantly declined since launch, with ongoing downward trends expected.
- Competition from newer regimens and generics will continue to erode market share.
- The trajectory suggests a transition from brand dominance to increased generic utilization by 2025-2027.
- Stakeholders should monitor patent status, regulatory policies, and international market dynamics.
FAQs
1. When is Sovaldi’s patent set to expire?
Major patents in the U.S. are expected to expire around 2027, enabling generic competition.
2. How do generic versions of sofosbuvir impact prices?
Generics typically cost 60-80% less, accelerating price declines and expanding access in emerging markets.
3. Are there regulatory hurdles for generic entry?
Yes, patent litigation and regulatory approvals can delay generic availability, affecting market timing.
4. How does Sovaldi’s efficacy compare to newer regimens?
While highly effective (SVR >90%), newer combination therapies offer broader genotypic coverage, shorter courses, and fewer side effects.
5. What strategies can Gilead adopt to sustain market relevance?
Developing next-generation therapies, securing patent extensions, and participating in negotiated pricing agreements can prolong product lifecycle.
Sources
[1] U.S. Food and Drug Administration. Sovaldi (sofosbuvir) approval history.
[2] IQVIA, 2023. Hepatitis C treatment market report.
[3] Gilead Sciences. 2023 Annual Report.
[4] CMS. Drug pricing and reimbursement data.
[5] Health Affairs. Impact of generic entry in hepatitis C treatment.
